Skip to main content
Top
Published in: Clinical Rheumatology 9/2019

01-09-2019 | Rheumatoid Arthritis | Original Article

Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis

Authors: Bogdan Batko, Karol Urbański, Jerzy Świerkot, Piotr Wiland, Filip Raciborski, Mariusz Jędrzejewski, Mateusz Koziej, Marta Cześnikiewicz-Guzik, Tomasz J. Guzik, Marcin Stajszczyk

Published in: Clinical Rheumatology | Issue 9/2019

Login to get access

Abstract

Introduction

Difficult-to-treat rheumatoid arthritis (RA) is a significant clinical problem despite no clear definition. We aimed to provide clinical characteristics and associated comorbidities of RA patients in relation to disease control.

Methods

RA characteristics and physician-recorded comorbidities were analyzed in a sample of 1937 RA patients. Patients treated for RA for 5.2 y (IQR, 2.1–11.3) were classified as difficult-to-control when presenting with DAS28-ESR > 3.2 despite previous use of at least 2 csDMARDs. A comparison of demographic and RA-related characteristics between difficult-to-treat and low disease activity patients (DAS28-ESR ≤ 3.2) was performed. Comorbidity burden was assessed by calculating Rheumatic Diseases Comorbidity Index (RDCI). Logistic regression model was constructed for difficult-to-control disease.

Results

Hypertension (46.9% (95%CI, 44.7–49.2)), coronary artery disease (CAD) (18.5% (95%CI, 16.8–20.3)), and diabetes (14.4% (95%CI, 12.9–16.0)) were the most prevalent conditions in RA patients. When compared with the adequate control group, difficult-to-control patients were increasingly burdened with hypertension (52.7% (95%CI, 47.5–57.8) vs. 42.0% (95%CI, 36.6–47.6); p = 0.006), cardiovascular diseases (24.2% (95%CI, 20.1–28.9) vs. 11.1% (95%CI, 8.0–15.1); p < 0.001), respiratory system diseases (7.0% (95%CI, 4.8–10.2) vs. 3.3% (95%CI, 1.8–5.9); p = 0.03) and gastroduodenal ulcers (2.3% (95%CI, 1.2–4.4) vs. 0.3% (95%CI, 0.1–1.8); p = 0.04). Patients with higher RDCI had lower chance to obtain low disease activity (OR 0.69 (95%CI, 0.61–0.79); p < 0.001). In multivariate analysis, RDCI was independently associated with difficult-to-control disease (OR 1.46 (95%CI, 1.21–1.76); p < 0.001).

Conclusions

RA patients suffer from a variety of comorbidities. Cardiovascular and respiratory system diseases occur twice as often in difficult-to-control patients. RDCI may provide a valuable tool in evaluating a risk for difficult-to-control RA.
Key Points
Hypertension, coronary artery disease and diabetes are the most prevalent comorbidities in rheumatoid arthritis.
Cardiovascular and respiratory tract diseases as well as gastroduodenal ulcers are more common among difficult-to-control patients, when compared with subjects with adequately controlled RA.
Rheumatic Diseases Comorbidity Index is an independent predictor for difficult-to-control RA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Roodenrijs NMT, de Hair MJH, van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D, Aletaha D, Dougados M, Hyrich KL, McInnes IB, Mueller-Ladner U, Senolt L, Szekanecz Z, van Laar JM, Nagy G, On behalf of the whole EULAR Task Force on development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis (2018) Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Ann Rheum Dis 77:1705–1709. https://doi.org/10.1136/annrheumdis-2018-213687 CrossRefPubMed Roodenrijs NMT, de Hair MJH, van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D, Aletaha D, Dougados M, Hyrich KL, McInnes IB, Mueller-Ladner U, Senolt L, Szekanecz Z, van Laar JM, Nagy G, On behalf of the whole EULAR Task Force on development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis (2018) Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Ann Rheum Dis 77:1705–1709. https://​doi.​org/​10.​1136/​annrheumdis-2018-213687 CrossRefPubMed
4.
go back to reference Kapetanovic M, Lindqvist E, Simonsson M, Geborek P, Saxne T, Eberhardt K (2010) Prevalence and predictive factors of comorbidity in rheumatoid arthritis patients monitored prospectively from disease onset up to 20 years: lack of association between inflammation and cardiovascular disease. Scand J Rheumatol 39:353–359. https://doi.org/10.3109/03009741003674180 CrossRefPubMed Kapetanovic M, Lindqvist E, Simonsson M, Geborek P, Saxne T, Eberhardt K (2010) Prevalence and predictive factors of comorbidity in rheumatoid arthritis patients monitored prospectively from disease onset up to 20 years: lack of association between inflammation and cardiovascular disease. Scand J Rheumatol 39:353–359. https://​doi.​org/​10.​3109/​0300974100367418​0 CrossRefPubMed
8.
go back to reference Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, Casado G, Detert J, el-zorkany B, Emery P, Hajjaj-Hassouni N, Harigai M, Luo SF, Kurucz R, Maciel G, Mola EM, Montecucco CM, McInnes I, Radner H, Smolen JS, Song YW, Vonkeman HE, Winthrop K, Kay J (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:62–68. https://doi.org/10.1136/annrheumdis-2013-204223 CrossRefPubMed Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, Casado G, Detert J, el-zorkany B, Emery P, Hajjaj-Hassouni N, Harigai M, Luo SF, Kurucz R, Maciel G, Mola EM, Montecucco CM, McInnes I, Radner H, Smolen JS, Song YW, Vonkeman HE, Winthrop K, Kay J (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:62–68. https://​doi.​org/​10.​1136/​annrheumdis-2013-204223 CrossRefPubMed
12.
go back to reference Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, Demary W, Burmester GR, Zink A (2006) Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low–results from RABBIT, the German biologics register. Arthritis Res Ther 8:R66. https://doi.org/10.1186/ar1933 CrossRefPubMedPubMedCentral Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, Demary W, Burmester GR, Zink A (2006) Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low–results from RABBIT, the German biologics register. Arthritis Res Ther 8:R66. https://​doi.​org/​10.​1186/​ar1933 CrossRefPubMedPubMedCentral
14.
go back to reference Biggioggero M, Mesina F, Favalli EG (2019) The use of rheumatic disease comorbidity index for predicting clinical response and retention rate in a cohort of rheumatoid arthritis patients receiving tumor necrosis factor alpha inhibitors. Biomed Res Int 2019:1–8. https://doi.org/10.1155/2019/6107217 CrossRef Biggioggero M, Mesina F, Favalli EG (2019) The use of rheumatic disease comorbidity index for predicting clinical response and retention rate in a cohort of rheumatoid arthritis patients receiving tumor necrosis factor alpha inhibitors. Biomed Res Int 2019:1–8. https://​doi.​org/​10.​1155/​2019/​6107217 CrossRef
16.
go back to reference Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJL, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DPM, Nurmohamed MT (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 76:17–28. https://doi.org/10.1136/annrheumdis-2016-209775 CrossRefPubMed Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJL, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DPM, Nurmohamed MT (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 76:17–28. https://​doi.​org/​10.​1136/​annrheumdis-2016-209775 CrossRefPubMed
18.
go back to reference Ferraz-Amaro I, Winchester R, Gregersen PK, Reynolds RJ, Wasko MC, Oeser A, Chung CP, Stein CM, Giles JT, Bathon JM (2017) Coronary artery calcification and rheumatoid arthritis: lack of relationship to risk alleles for coronary artery disease in the general population. Arthritis Rheum 69:529–541. https://doi.org/10.1002/art.39862 CrossRef Ferraz-Amaro I, Winchester R, Gregersen PK, Reynolds RJ, Wasko MC, Oeser A, Chung CP, Stein CM, Giles JT, Bathon JM (2017) Coronary artery calcification and rheumatoid arthritis: lack of relationship to risk alleles for coronary artery disease in the general population. Arthritis Rheum 69:529–541. https://​doi.​org/​10.​1002/​art.​39862 CrossRef
21.
go back to reference Fujii M, Adachi S, Shimizu T, Hirota S, Sako M, Kono M (1993) Interstitial lung disease in rheumatoid arthritis: assessment with high-resolution computed tomography. J Thorac Imaging 8:54–62CrossRefPubMed Fujii M, Adachi S, Shimizu T, Hirota S, Sako M, Kono M (1993) Interstitial lung disease in rheumatoid arthritis: assessment with high-resolution computed tomography. J Thorac Imaging 8:54–62CrossRefPubMed
Metadata
Title
Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis
Authors
Bogdan Batko
Karol Urbański
Jerzy Świerkot
Piotr Wiland
Filip Raciborski
Mariusz Jędrzejewski
Mateusz Koziej
Marta Cześnikiewicz-Guzik
Tomasz J. Guzik
Marcin Stajszczyk
Publication date
01-09-2019
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 9/2019
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04579-1

Other articles of this Issue 9/2019

Clinical Rheumatology 9/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine